I’m seeing openings that bundle FDA submissions with ethics oversight. In the last month, three postings asked for 510(k)/IND leadership plus owning eCTD sequences and drafting ICH E6(R2)/GCP and trial transparency policies — is this the new normal, and how are you negotiating scope and title when submissions and ethics live in one seat?